Works matching IS 15391604 AND DT 2025 AND VI 24 AND IP 2
Results: 32
Average Hazard as Harmonic Mean.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.70009
- By:
- Publication type:
- Article
Using Subject Level Covariate Information in Bayesian Mixture Models for Basket Trials.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.70006
- By:
- Publication type:
- Article
Success and Futility Criteria for Accelerated Approval of Oncology Drugs.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.70004
- By:
- Publication type:
- Article
A Federated Data Analysis Approach for the Evaluation of Surrogate Endpoints.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.70003
- By:
- Publication type:
- Article
Interval Estimation for the Youden Index and Optimal Cut‐Off Point in AUC‐Based Optimal Combinations of Multivariate Normal Biomarkers With Covariates.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.70001
- By:
- Publication type:
- Article
Getting (More Out of) Graphics—Practices and Principles of Data Visualisation. Data Science Series.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.70000
- By:
- Publication type:
- Article
Approximate Bayesian Analysis for Borrowing External Controls for Randomized Controlled Trials With Dynamic Borrowing and Covariate Balancing Adjustment.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2474
- By:
- Publication type:
- Article
Trial Probability of Success for Testing 3‐Way PK/PD Similarity With Multiple Endpoints.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2473
- By:
- Publication type:
- Article
Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 Trial.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2472
- By:
- Publication type:
- Article
Using Propensity Score Weighting to Enhance the Operating Characteristics of Power Prior in Leveraging External Data to Augment a Traditional Clinical Study.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2471
- By:
- Publication type:
- Article
BF‐BOIN‐ET: A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose Optimization.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2470
- By:
- Publication type:
- Article
A Bayesian Hybrid Design With Borrowing From Historical Study.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2466
- By:
- Publication type:
- Article
WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2463
- By:
- Publication type:
- Article
A Phase I Dose‐Finding Design Incorporating Intra‐Patient Dose Escalation.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2461
- By:
- Publication type:
- Article
Flexible Spline Models for Blinded Sample Size Reestimation in Event‐Driven Clinical Trials.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2459
- By:
- Publication type:
- Article
Confidence Intervals for the Risk Difference Between Secondary and Primary Infection Based on the Method of Variance Estimates Recovery.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2458
- By:
- Publication type:
- Article
Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2457
- By:
- Publication type:
- Article
Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2456
- By:
- Publication type:
- Article
Subgroup Identification Based on Quantitative Objectives.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2455
- By:
- Publication type:
- Article
A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2454
- By:
- Publication type:
- Article
Potential Bias Models With Bayesian Shrinkage Priors for Dynamic Borrowing of Multiple Historical Control Data.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2453
- By:
- Publication type:
- Article
Beyond the Fragility Index.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2452
- By:
- Publication type:
- Article
A Bayesian Dynamic Model‐Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2451
- By:
- Publication type:
- Article
Pre‐Posterior Distributions in Drug Development and Their Properties.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2450
- By:
- Publication type:
- Article
Treatment Effect Measures Under Nonproportional Hazards.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2449
- By:
- Publication type:
- Article
Comparison of Prior Distributions for the Heterogeneity Parameter in a Rare Events Meta‐Analysis of a Few Studies.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2448
- By:
- Publication type:
- Article
Prediction Intervals for Overdispersed Poisson Data and Their Application in Medical and Pre‐Clinical Quality Control.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2447
- By:
- Publication type:
- Article
Optimizing Sample Size Determinations for Phase 3 Clinical Trials in Type 2 Diabetes.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2446
- By:
- Publication type:
- Article
A Likelihood Perspective on Dose‐Finding Study Designs in Oncology.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2445
- By:
- Publication type:
- Article
PKBOIN‐12: A Bayesian Optimal Interval Phase I/II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2444
- By:
- Publication type:
- Article
Bayesian Response Adaptive Randomization for Randomized Clinical Trials With Continuous Outcomes: The Role of Covariate Adjustment.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2443
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2025, v. 24, n. 2, p. 1, doi. 10.1002/pst.2401
- Publication type:
- Article